Appello Pharmaceuticals

Executive Summary

Appello Pharmaceuticals is a private, early-stage biotech company focused on developing small molecule therapies for neurological disorders. Founded in 2019 and headquartered in San Diego, the company aims to address the growing global burden of neurological diseases, which have seen rising incidence and mortality over the past 25 years. Despite significant advances in understanding brain biology, pharmaceutical innovation has lagged behind disease prevalence. Appello seeks to bridge this gap by translating recent research insights into novel drug candidates that can improve outcomes for patients suffering from conditions such as Alzheimer's, Parkinson's, and other central nervous system disorders. As a private entity with no disclosed revenue or pipeline details, the company operates in a highly competitive and capital-intensive space, relying on strategic partnerships and funding to advance its preclinical and early clinical programs.

Upcoming Catalysts (preview)

• Q3 2026Initiation of First-in-Human Phase 1 Trial for Lead Candidate65% success
• Q1 2027Presentation of Preclinical Efficacy Data at Major Neurology Conference70% success
• Q4 2026Series A Funding Announcement to Support Pipeline Expansion80% success